La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Nevro Bilan de santé

Santé financière contrôle des critères 5/6

Nevro possède un total de capitaux propres de $274.3M et une dette totale de $218.4M, ce qui porte son ratio d'endettement à 79.6%. Son actif total et son passif total sont $603.3M et de $329.1M.

Informations clés

79.6%

Ratio d'endettement

US$218.40m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$273.69m
Fonds propres	US$274.25m
Total du passif	US$329.08m
Total des actifs	US$603.34m

Mises à jour récentes de la santé financière

Recent updates

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Aug 11

Nevro: Not Having My Back

Aug 09

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jul 16

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

May 01

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Feb 25

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Jan 08

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nov 16

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Sep 01

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Jul 10

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Feb 28

Nevro falls to 52-week low; down ~49% over last year

Feb 22

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Feb 14

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jan 13

Nevro: Opportunity Overshadowed By Weaknesses

Dec 07

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Oct 26

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Oct 13

Nevro gets FDA approval for Costa Rica manufacturing operations

Oct 04

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Oct 02

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Sep 07

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Jun 17

Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery

Jun 10

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NVRO ( $486.2M ) dépassent ses passifs à court terme ( $101.9M ).

Passif à long terme: Les actifs à court terme de NVRO ( $486.2M ) dépassent ses passifs à long terme ( $227.1M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: NVRO dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de NVRO est passé de 77.5% à 79.6% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NVRO dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NVRO dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 9.5 % chaque année

Nevro Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Recent updates

Consensus EPS estimates fall by 21%

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Nevro: Not Having My Back

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 25% to US$11.07

Nevro Revises Earnings Guidance for the Full Year 2024

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$2.31 loss

Price target decreased by 12% to US$16.63

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro Corp. Announces Executive Changes

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Consensus forecasts updated